Shanghai Shyndec Pharmaceutical (600420.SH) issued an announcement. Recently, the company's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd. (...)
Futubull Financial APP News, Shanghai Shyndec Pharmaceutical (600420.SH) issued an announcement. Recently, the company's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd. (referred to as China National Pharmaceutical Industry), received the approval notice for the listing application of chemical raw materials drugs issued by the National Medical Products Administration, approving the listing application of clonazepam.
Clonazepam is a benzodiazepine-class drug and belongs to the second category of psychotropic drugs. It is mainly used to control various types of epileptic seizures, especially for absence seizures, infantile spasms, myoclonic seizures, atonic seizures, and Lennox-Gastaut syndrome. This time, China National Pharmaceutical Industry's clonazepam obtained the approval notice for the listing application of chemical raw materials drugs, indicating that the raw material drug meets the relevant national drug approval technical standards and can be produced and sold, which will further enrich the company's anesthesia and psychiatric sector's product line and help expand the company's product areas. The above-mentioned matters will not have a significant impact on the company's current operating performance.
